You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Preclinical development of novel small molecule malaria drugs that overcome drug
SBC: DESIGNMEDIX, INC. Topic: NIAIDDESCRIPTION (provided by applicant): The worldwide health problem created by malaria has been made more difficult by the spread of drug- resistant parasites. This project initiates preclinical development of one or more candidate(s) from an innovative newclass of potent antimalarials designed to overcome drug resistance. We have developed an orally available and inexpensive class of novel drugs th ...
STTR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health -
FAH-Deficient Pigs
SBC: Yecuris Corporation Topic: NIDDKDESCRIPTION (provided by applicant): Translational research in the field of liver disease has been limited by a shortage of large animal models, which in turn has limited development of new therapies for metabolic liver disorders, acute liver failure, chronic (cirrhotic) liver disease, an hepatocellular carcinoma. While new transgenic and knockout rodent models of liver disease have facilitated ba ...
STTR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health -
Novel Topical Therapy for Diabetic Retinopathy using Beta-Adrenergic Receptor Ago
SBC: MOLECULAR DESIGN INTERNATIONAL, INC. Topic: NEIDESCRIPTION (provided by applicant): The overall goal of our work is to establish the potency and efficacy of a novel 2-adrenergic receptor agonist (compound 49b) in the prevention and/or reversal of non-proliferative diabetic retinopathy. Diabetic retinopathy is the leading cause of blindness in working age adults. The current treatment paradigm for retinopathy patients has not changed signif ...
STTR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health -
Novel Azaborine Derivatives Predicted to Eliminate Acetaminophen Hepatotoxicity
SBC: QUINTESSENCE CHEMICALS, LLC Topic: NIGMSDESCRIPTION (provided by applicant): Overdose on acetaminophen (more commonly known by the brand name Tylenol(R)), accounts for 56,000 emergency room visits and more than 450 deaths annually in the USA. Acetaminophen overdose can occur by a single event ofexceeding the recommended daily dosage. Overdose on acetaminophen is facilitated by the fact that it is a common ingredient in over-the-counter ...
STTR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health -
Advanced Bicycle Helmet Technology for Prevention of Traumatic Brain Injury
SBC: Apex Biomedical Company, LLC Topic: NINDSDESCRIPTION (provided by applicant): Traumatic brain injury (TBI) is an acquired neurological disorder that can cause long-lasting disability with limited treatment options. Therefore preventative strategies must be emphasized in high-risk activities to reduce the individual and societal burden of this pervasive injury. Bicycle activities account for 20 percent of all sports-related TBI, with ...
STTR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health -
Computer assisted disfluency counts for stuttered speech
SBC: BIOSPEECH INC Topic: NIDCDDESCRIPTION (provided by applicant): Stuttering is a communication disorder characterized by disfluencies that may be frequent or disruptive to communication. Clinicians make extensive use of disfluency counts, for diagnosis, to assess treatment progress,and to document treatment outcomes. SLPs mostly do disfluency counts in real-time as a client is talking. However, this approach only accounts fo ...
STTR Phase II 2011 Department of Health and Human ServicesNational Institutes of Health -
DNA Repair Enzymes for the Prevention of Skin Cancer
SBC: RESTORATION GENETICS, INC. Topic: NIEHSDESCRIPTION (provided by applicant): Current health care modalities for humans diagnosed with either precancerous actinic keratoses or skin cancers (including basal and squamous cell carcinomas) primarily involve surgical excision of the lesions or chemical or photodynamic burning of the affected tissues. These post-diagnostic treatments are directed to disease management, while disease prevention ...
STTR Phase II 2011 Department of Health and Human ServicesNational Institutes of Health -
Interactive Multimedia Training for First Steps to Success
SBC: DESCHUTES RESEARCH, INC. Topic: NICHDDESCRIPTION (provided by applicant): In the past decade, elementary school settings have been overwhelmed by increasing numbers of behaviorally at-risk children who are unresponsive to the minimal but necessary demands of schooling. It is of critical importance to get behaviorally at-risk children off this trajectory or pathway as soon as possible in their school careers through early, coordinated ...
STTR Phase II 2011 Department of Health and Human ServicesNational Institutes of Health -
Quantum-Confined Nanocrystal Materials for Anti-Stokes Optical Coolers
SBC: VOXTEL, INC. Topic: AF10BT02ABSTRACT: Nanocrystals (NCs) offer many potential benefits for optical refrigeration; these quantum-confined materials have discrete energy levels, large optical transition dipole moments, and high photoluminescence quantum efficiency. Using well-characterized upconverting ion-doped metal oxide NCs and core-shell semiconductor nanocrystals as a baseline, a design of experiments (DOE) will be cond ...
STTR Phase I 2011 Department of DefenseAir Force -
In Vivo Expansion of Human Hepatocytes in FRG Mice
SBC: Yecuris Corporation Topic: NCRRDESCRIPTION (provided by applicant): The FDA requires the use of human hepatocytes for preclinical drug testing by pharmaceutical researchers, but unfortunately the supply of these cells is severely limited. Currently, cadaveric donors and surgical liver resection specimens are currently the only available source of human hepatocytes. These samples are very scarce and often yield cells of poor qua ...
STTR Phase II 2011 Department of Health and Human ServicesNational Institutes of Health